CRISPR Cell Lines

Dr. Frank Weise
dep. Head of Department Pharma & Biotech
Group Leader Cell- & Molecular Biology

+49 7121 51530-56

E-Mail

CRISPR/Cas9 genome editing services

As part of our extensive experience in creating customized stable cell lines, we also use CRISPR/Cas9 genome editing to develop your specific cell models. Work is covered by a set of license agreements assuring freedom to operate (FTO).

Our range of services includes

• The generation of target-defective / knockout cell lines,
• The introduction of larger genomic deletions in a cell line of choice,
• The generation of mutant cell clones bearing hemi- or homozygous point-/missense mutations introduced by homology-directed-repair (HDR),
• The generation of (reporter-) cell lines endogenously expressing fusion proteins after HDR-mediated genome editing, 
• Generation of synthetic human iPSC disease models,
• CRISPR/Cas9 genome editing of primary T cells.

Beyond the generation of custom cell lines, CRISPR/Cas9 technology is also integrated into our target validation workflows, serving a role analogous to RNAi-mediated gene silencing.